INS and type 1 diabetes mellitus: Data from a real‐life study in obese (mean BMI of 35.4 kg/m2) T1D individuals with moderate glucose control (HbA1c 7.3%, time in range 74% and time below range 1%) while on automated insulin delivery demonstrate that adding a GLP‐1RA to background insulin treatment (Liraglutide or Semaglutide), compared to placebo, resulted in mean body weight reduction of 11% and a reduction in daily insulin requirement by 15 units after 6 months [59].